Risks and benefits of bone marrow transplantation in children

Overview of Bone Marrow Transplantation

• Bone marrow transplantation, or hematopoietic stem cell transplantation (HSCT), is a therapeutic procedure utilizing allogeneic (donor-derived) or autologous (patient-derived) stem cells to treat a wide variety of malignant and nonmalignant conditions.
• The procedure involves a preparative conditioning regimen utilizing chemotherapy and/or irradiation to eliminate the host’s hematopoietic system, suppress the immune system to prevent rejection, and significantly reduce tumor burden in cases of malignancy.
• The infused graft contains mature blood cells, including T cells, natural killer (NK) cells, and dendritic cells, which repopulate the recipient’s lymphohematopoietic system and provide a critical graft-versus-leukemia (GVL) effect by eliminating residual malignant cells.

Benefits and Clinical Indications

Malignant Disorders

• In acute lymphoblastic leukemia (ALL), allogeneic HSCT benefits pediatric patients in their first complete remission if they exhibit high-risk features, or in second or subsequent remissions, achieving a 3-year overall survival rate of 70–80%.
• For acute myeloid leukemia (AML), HSCT serves as a robust postremission consolidation therapy for high-risk patients, yielding better event-free survival than chemotherapy alone, with a 3-year overall survival of 60–70%.
• HSCT is a proven curative treatment for chronic myelogenous leukemia (CML), with leukemia-free survival reaching 45–80%, though its upfront use is now generally reserved for patients who fail or cannot tolerate tyrosine kinase inhibitor therapy.
• In juvenile myelomonocytic leukemia (JMML), HSCT cures approximately 50–60% of patients, overcoming the otherwise aggressive and rapidly fatal natural history of the disease.
• For relapsed or refractory Hodgkin and non-Hodgkin lymphomas, as well as high-risk solid tumors like neuroblastoma and brain tumors, autologous HSCT offers survival rates of 50–60% for patients with sensitive disease and minimal tumor burden.

Non-Malignant Disorders

• The most favorable HSCT outcomes are often achieved in non-malignant congenital or acquired disorders, as the risk of disease recurrence is extremely low and transplantation-related mortality is substantially reduced compared to malignant conditions.
• HSCT is the definitive and potentially curative treatment for severe combined immunodeficiency (SCID), achieving a 95% survival rate when performed optimally within the first 100 days of life.
• Other primary immunodeficiencies successfully cured by HSCT include Wiskott-Aldrich syndrome (where survival approaches 100% with a matched sibling), hyper-IgM syndrome, leukocyte adhesion deficiency, and chronic granulomatous disease (CGD).
• For acquired severe aplastic anemia, matched-sibling bone marrow transplantation provides a long-term survival probability exceeding 80%.
• Inherited bone marrow failure syndromes, such as Fanconi anemia, are cured of their aplastic anemia and protected from subsequent clonal hematopoietic disorders via HSCT, with a 5-year overall survival greater than 90% if performed prior to leukemic transformation.
• HSCT is currently the only curative treatment for hemoglobinopathies; in thalassemia major patients without significant liver damage who have received regular iron chelation, the probability of survival with complete transfusion independence exceeds 90%.
• In sickle cell disease, HSCT offers an 80–90% probability of cure for patients experiencing severe vasoocclusive crises or strokes, effectively halting disease progression.
• For inherited metabolic diseases like mucopolysaccharidosis type 1 (Hurler syndrome) and adrenoleukodystrophy, HSCT enables the engraftment of microglial cells that deliver necessary enzymes directly to the central nervous system, preventing irreversible neurologic damage.

Risks and Complications

Graft-Versus-Host Disease (GVHD)

• Acute GVHD is a major cause of morbidity and mortality, occurring when alloreactive donor T cells recognize recipient tissues as foreign, leading to a massive inflammatory attack primarily targeting the skin, liver, and gastrointestinal tract.
• Significant acute GVHD develops in approximately 30% of matched sibling recipients and up to 60% of unrelated donor recipients, typically manifesting within the first 2 to 8 weeks post-transplant.
• Severe (Grade IV) acute GVHD is a life-threatening and often fatal condition characterized by generalized erythroderma, severe liver impairment, and gross gastrointestinal bleeding or ileus.
• Chronic GVHD occurs months to years after transplantation and represents the leading cause of nonrelapse mortality and morbidity in long-term survivors.
• Chronic GVHD functions as a systemic disorder of immune regulation, producing severe autoimmune-like symptoms such as scleroderma, sicca syndrome, progressive bronchiolitis obliterans, and cirrhosis, which profoundly impact the patient’s quality of life.

Infectious Complications

• HSCT recipients experience a transient but profound state of immune deficiency, making life-threatening infections a leading risk.
• In the preengraftment phase (the first 30 days), severe neutropenia and conditioning-induced mucosal damage place patients at extreme risk for bacterial sepsis and invasive fungal diseases caused by Candida and Aspergillus species.
• In the postengraftment phase, delayed T-cell and B-cell recovery predisposes patients to severe viral infections, notably cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, and varicella-zoster virus.
• CMV pneumonia carries a massive case fatality rate of 85% in the absence of early antiviral treatment, while EBV reactivation can lead to fatal posttransplant lymphoproliferative disease (PTLD).

Graft Failure and Rejection

• Primary graft failure (the failure to achieve a neutrophil count of 0.5 × 10^9/L) or secondary graft failure (the loss of peripheral counts after initial transient engraftment) exposes patients to a high risk of fatal infection.
• Graft rejection is typically mediated immunologically by residual host T-lymphocytes surviving the conditioning regimen, and the risk is highest in HLA-disparate transplants, T-cell–depleted grafts, or when utilizing reduced-intensity conditioning regimens.

Venoocclusive Disease (VOD)

• Also known as sinusoidal obstruction syndrome, VOD results from conditioning-induced endothelial damage within the liver.
• It typically presents within 30 days of transplantation with marked hepatomegaly, right upper quadrant tenderness, jaundice, fluid retention, and ascites.
• The severe form of VOD can rapidly progress to multiorgan dysfunction and carries a mortality rate exceeding 80% if untreated.

Late Effects and Organ Toxicity

• Endocrine complications include severe growth impairment (particularly due to total body irradiation affecting the hypothalamic-pituitary axis and cartilage plates), primary ovarian or testicular failure, delayed puberty, and a high risk of permanent infertility.
• Patients are at elevated risk for metabolic syndrome, dyslipidemia, and cardiotoxicity, especially if exposed to pre-transplant anthracyclines or chest radiation.
• The risk of developing secondary malignancies, such as myelodysplastic syndromes, secondary leukemias, thyroid carcinoma, and brain tumors, is significantly elevated compared to the general pediatric population.
• Neurocognitive deficits and progressive leukoencephalopathy can occur, particularly in young children who receive total body irradiation or cranial radiation.
• Other long-term complications include restrictive pulmonary disease, renal toxicity, cataracts, dental abnormalities, and significant psychological late effects including depression, anxiety, and posttraumatic stress.